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Background: Aspirin-intolerant asthma is a unique clinical syndrome characterized by acute
bronchoconstriction following the administration of aspirin and/or non-steroidal anti-inflam-
matory drugs.
Objective: We assessed the prevalence and investigated the demographic and clinical charac-
teristics of adult patients with aspirin-intolerant asthma in Korea.
Methods: Using an adult asthma cohort (COREA) from 11 university hospitals in Korea, we
analyzed the prevalence of aspirin-intolerant asthma, defined as a positive response to the
question: “Have you ever experienced dyspnea and cough after taking an aspirin or any NSAID
(cold medicine)?” Demographic and clinical characteristics were compared between patients
with aspirin-intolerant asthma and aspirin-tolerant asthma.2290 8349; fax: þ82 2 2298 9183.
c.kr (H.J. Yoon).
2 Published by Elsevier Ltd.
12.10.020
Aspirin-intolerant asthma in adult asthmatics 203Results: Aspirin-intolerant asthma was reported in 68 (5.8%) of 1173 adult asthmatics (age 15
e84). Patients with aspirin-intolerant asthma had a lower mean age (43.9  13.4 vs.
49.0  15.6, P Z 0.003) and a higher prevalence of rhinosinusitis (77.9% vs. 61.7%,
P Z 0.012) and atopic dermatitis (16.2% vs. 5.7%, P Z 0.001) than aspirin-tolerant asthma
patients. There were no significant differences in lung function, asthma severity or the use
of asthma controllers. However, aspirin-intolerant asthma was associated with greater use
of healthcare services over a lifetime and over the past 12 months. Aspirin-intolerant asthma
was significantly associated with emergency room visits over the past 12 months (P Z 0.029,
OR 2.19, 95% CI 1.08e4.42).
Conclusion: Based on histories, the prevalence of aspirin-intolerant asthma is 5.8% among
adult asthma patients in Korea. Aspirin-intolerant asthma is associated with lower age, higher
prevalence of rhinosinusitis and atopic dermatitis, and more frequent exacerbations.
ª 2012 Published by Elsevier Ltd.Introduction
Asthma is a chronic inflammatory disease of the airways
characterized by recurrent attacks of breathlessness, chest
tightness, and wheezing. Some patients with asthma
experience acute reactions to aspirin and other non-
steroidal anti-inflammatory drugs (NSAIDs).1e4 Aspirin-
intolerant asthma (AIA) is a distinct syndrome associated
with more severe asthma, severe rhinosinusitis with
recurrent nasal polyposis, and precipitation of asthma and
rhinitis attacks by ingestion of aspirin.1,3e8 This syndrome is
increasingly being termed aspirin-exacerbated respiratory
disease (AERD), emphasizing the underlying inflammation
of the respiratory tract as the fundamental disease and
aspirin/NSAIDs as an intensifying.7e11 This indicates that,
despite appropriate avoidance of aspirin and NSAIDs, AIA
does not resolve and runs a protracted course.3,12,13 AIA-
associated acute exacerbations of asthma are clinically
important and costly. Accordingly, identifying aspirin
sensitivity is essential for the treatment of patients with
asthma in order to prevent and manage frequent acute
exacerbations that could be related to aspirin sensitivity.
To date, several studies have used questionnaire surveys
to assess the prevalence of aspirin-intolerance in the
general population and in patients with asthma. The re-
ported prevalence of AIA ranges from 4.3% to 14% in
asthmatics14e18 and from 0.6% to 2.5% in the general pop-
ulation.15e17 Estimates of the prevalence of AIA vary
according to the methodological approach, which has
included aspirin challenge tests, postal questionnaire
surveys, and face-to-face interviews.19 In a meta-analysis
of 15 studies, the prevalence rates were 21% based on
oral aspirin challenge and 2.7% based on patient histories.19
In addition, the variation in measured prevalence of AIA
depends considerably on the population assessed. Most
studies of the prevalence and clinical characteristics of AIA
have been on Western populations, and there are no clin-
ical data from large cohort studies involving East Asian
patients. Since ethnic disparities have been observed in the
prevalence and characteristics of asthma,20e23 research on
Asian patients suffering from AIA would be useful. More-
over, the reported demographic and clinical features of
AIA, including female predominance and atopic traits,
have been inconsistently observed. Therefore, the aims
of the present study were to investigate the prevalence,demographics, and clinical characteristics of aspirin-
intolerance in Korean adult cohorts with asthma.Materials and methods
Subjects
The COhort for Reality and Evolution of Adult Asthma in
Korea (COREA) is a 9-year (2005e2013), multicenter,
prospective cohort study of patients aged 19 years or older
suffering from asthma. The design and methods of the
COREA study have been described previously.24 Briefly, the
patients were enrolled from 11 clinical centers in various
regions of South Korea. Asthma was diagnosed by allergy or
pulmonology professionals based on symptoms, clinical
course and positive responses to the methacholine bron-
chial provocation test or short-acting bronchodilator test.
Patients with obvious chronic obstructive pulmonary
disease (COPD) and acute exacerbation within the previous
month were excluded. The enrolled patients underwent
radiologic studies, sprirometry, skin prick tests, and labo-
ratory tests including sputum examination. The methods
used and criteria for a positive response have been
described in a previous study.25 Briefly, skin prick tests
were performed for common aeroallergens including house
dust mites (Dermatophagoides pteronyssinus and Derma-
tophagoides farinae), tree pollen mixture, grass pollen
mixture, ragweed, mugwort, cockroach, alternaria, asper-
gillus, cat and dog. A positive control with histamine (1 mg/
mL) and a negative diluent control were included in all
tests. A wheal size of 3 mm or more was considered posi-
tive, and atopy was defined as one or more positive
responses to allergens. Patients were interviewed at
enrollment via a questionnaire assessing frequency and
duration of symptoms, patterns of hospital use, and
smoking status. They were reevaluated and treated by
allergy or pulmonology physicians based on the Global
Initiative for Asthma (GINA) guidelines26 every 3 months
(30 days) during the follow-up period. The presence of
rhinosinusitis in a given subject was determined by the
physicians in charge of that patient. Subjects with atopic
dermatitis were those who answered ‘yes’ to the question
‘Have you ever been diagnosed with atopic dermatitis by
a doctor?’. Starting with the second visit in the third month,
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visit. Of the 1,965 subjects enrolled in COREA, 1,173, who
reported either presence or absence of asthma exacerba-
tion following the intake of aspirin or non-steroidal anti-
inflammatory drugs (NSAIDs), were analyzed. All subjects
were ethnic Koreans and provided written informed
consent. The research protocol for this cohort study was
approved by the institutional review board of each center.
Definition of aspirin-intolerant asthma
Patients with AIA were distinguished from patients with
aspirin-tolerant asthma (ATA) by the question: “Have you
ever experienced dyspnea and cough after taking an aspirin
or any NSAID (cold medicine)?” The patients were also
asked if they had experienced urticaria/edema after taking
an aspirin or any NSAID (cold medicine). Subjects who
experienced cough or dyspnea after taking drugs such as
fever remedies, analgesics, and aspirin were classified as
having AIA.
Characteristics and severity of asthma
At study entry we examined the clinical features of all the
patients. Atopy was defined by one or more positive reac-
tion in the skin prick tests; airway hyperresponsiveness in
the methacholine challenge test was used to diagnose
asthma; and the severity of allergic rhinosinusitis was
diagnosed by physicians. The severity of asthma was also
assessed by physicians and by the use of controller medi-
cation, based on the GINA guidelines and the number and
types of controllers, respectively.
Acute exacerbation and the control of asthma
Levels of asthma control were based on frequencies of
acute exacerbation in the previous year and the ACT scores
in the third month. Severity and frequency of asthma
exacerbation were assessed by using the following ques-
tions: “Have you ever visited or been admitted to a hospital
due to an acute exacerbation of cough, dyspnea, or
wheezing?”; “If you have, how many times have you visited
or been admitted?”; “If you have, how many times were you
visited or admitted in the past year?” Subjects counted the
number of times each of these events had occurred
including any unscheduled outpatient clinic (OPD) visits,
emergency room (ER) visits, and admissions to a general
hospital ward or to an intensive care unit (ICU).
Statistical analyses
Data from the subjects with AIA and ATA were compared.
The KolmogoroveSmirnov test was used to analyze the
distribution of variables. According to the distribution,
Student’s t-test or the ManneWhitney U test was used to
analyze continuous outcomes including age at baseline
(years), BMI (in kilograms per square meter), duration of
symptoms, duration of treatment, serum total IgE,
percentage of eosinophils among peripheral blood leuko-
cytes and PC20 in the bronchial challenge test. The c
2 test
was used for categorical variables including gender,presence of rhinosinusitis, aspirin-induced urticaria, history
of atopic dermatitis, and positive skin test. Due to differ-
ences in the demographic characteristics of the two groups,
models were developed to adjust for covariates including
age at baseline, gender, BMI, positive skin test, presence of
allergic rhinitis, and smoking status; multivariate regression
analysis was used for spirometry (FEV1, FVC and the FEV1/
FVC ratio before and after administration of a b-agonist),
healthcare use, and ACT scores; multivariate logistic
regression analysis was used for asthma severity assessed
by physician, and medication data. P-values below 0.05
were considered statistically significant. Data were
analyzed using SPSS software (version 17.0, Chicago, USA).
Results
Prevalence and demographic characteristics of
patients with AIA
Of the 1,173 adult subjects with asthma enrolled in the
study, 68 (5.8%) were identified as AIA from the question-
naire. The demographic and clinical characteristics of these
patients and those with ATA are presented in Table 1.
Sixteen patients under the age of 19 were ineligible for
inclusion in this cohort but were enrolled and included in all
the analyses. Patients with AIA were younger than those
with ATA (43.9  13.4 vs. 49.0  15.6 years, P Z 0.003).
Patients in the two groups had similar body mass index and
durations of symptoms and treatment. The patients with
AIA were more likely to have rhinosinusitis (77.9% vs. 61.7%,
P Z 0.012) and atopic dermatitis (16.2% vs. 5.7%,
PZ 0.001). Similar frequencies of positive test results were
reported among the patients who had undergone the
bronchial challenge test and the allergy skin test. There
were no significant differences in total IgE levels and
eosinophil percentages in peripheral blood. Aspirin-induced
urticaria was more common in the patients with AIA (49.2%
vs. 2.7%, P < 0.001).
Lung function
Spirometric data are summarized in Table 2. There were no
significant difference of pre- or post-bronchodilator spiro-
metric indices between the patients with AIA and those
with ATA. These findings were not affected by adjustment
for confounding factors such as age, gender, BMI, positive
skin test, smoking status, and presence of allergic rhinitis.
Asthma severity
Asthma severity was determined by a physician based on
the GINA classification and compared in patients with AIA
and ATA (Table 3). Among the patients with AIA, 27.9% were
considered to have severe asthma, almost the same as the
26.4% among the ATA patients. There were no significant
differences in the ratios of different levels of asthma
severity in the two groups. We also analyzed current use of
asthma controllers to assess asthma severity in the AIA and
ATA patients. The proportions of subjects using three or
more controllers were similar in the AIA (32.4%) and ATA
Table 2 Lung functions based on pre- and post-
bronchodilator spirometry.
AIA
(n Z 68)
ATA
(n Z 1105)
P-value
Prebronchodilator
FEV1, L 2.4  0.8 2.3  0.9 NS
FEV1 % predicted 82.9  21.8 82.7  21.5 NS
FVC, L 3.3  0.8 3.1  1.0 NS
FVC % predicted 92.0  19.5 88.4  17.3 NS
FEV1/FVC 73.4  12.2 73.6  12.8 NS
Post-bronchodilator
spirometry
FEV1, L 2.5  0.7 2.4  0.9 NS
FEV1 % predicted 86.6  20.6 85.3  22.1 NS
FVC, L 3.4  0.7 3.2  0.9 NS
FVC % predicted 91.1  14.6 88.3  16.7 NS
FEV1/FVC 75.8  13.4 74.9  12.9 NS
Values are presented as mean  SD. AIA, aspirin-intolerant
asthma; ATA, aspirin-tolerant asthma; NS, not significant.
Table 1 Demographic and clinical characteristics of patients with aspirin-intolerant asthma (AIA) and aspirin-tolerant asthma
(ATA).
AIA (n Z 68) ATA (n Z 1105) P-value*
Female 41 (60.3%) 597 (54.0%) NS
Age, years 43.9  13.0 49.0  15.6 0.003
BMI, kg/m2 23.1  3.3 23.9  3.3 NS
Duration of symptoms, years 10.1  9.9 8.0  10.3 NS
Duration of treatment, years 5.4  5.8 4.2  5.4 NS
Smoking (current/past/never) 11 (16.4)/30
(44.8)/26 (38.8)
175 (16.1)/442
(40.6)/473 (43.4)
NS
PC20, mg/ml 3.7  4.4 4.0  3.9 NS
Rhinosinusitis 53 (77.9) 682 (61.7) 0.012
Aspirin induced urticaria 33 (49.2) 30 (2.7) <0.001
Atopic dermatitis 11 (16.2) 63 (5.7) 0.001
Positive skin test 36 (52.4) 488 (44.2) NS
Serum total IgE, IU/mL 410.2  932.3 392.9  611.1 NS
Peripheral blood eosinophil, % 5.5  4.5 6.5  46.2 NS
Continuous values are presented as mean  SD, and categorical variables as numbers (%). AIA, aspirin-intolerant asthma; ATA, aspirin-
tolerant asthma; NS, not significant; BMI, body mass index. *P-values less than 0.05 were considered significant.
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proportion of subjects using asthma controllers. Although
the guidelines recommend leukotriene receptor antagonists
(LTRA) for the treatment of AIA, there was no difference
between the use of LTRA in the two groups (26.5% vs.
23.2%). The severity of AIA based on physician assessment
and controller use was comparable to that of ATA even
after adjusting for potential confounding variables such as
age, gender, BMI, and allergic conditions.
Healthcare utilization and current control status
As the frequency of acute exacerbations is a key determi-
nant of asthma control, we examined whether aspirin
sensitivity was associated with an increased risk of acute
exacerbations. Our data indicated that significantly more
patients with AIA used healthcare services for asthma both
over their lifetime and over the previous 12 months (Table
4). In particular, visits to the ER were more common in AIA
patients than in ATA patients (11.8% vs. 6.4%, P Z 0.029).
The number of unscheduled OPD visits and hospitalizations
was also higher in AIA patients, but the difference was not
statistically significant.
We also compared overall asthma control status using
the ACT scores. The mean total ACT score in AIA patients
was not significantly different from that in ATA patients
(20.8  3.3 vs. 20.6  3.2, P Z 0.352). This suggests that
the overall asthma-control status in AIA is comparable to
that in ATA. Nonetheless, frequent exacerbation of asthma
is an important feature of AIA.
Discussion
This is the first report on the prevalence of AIA in Asian
asthmatic patients based on a large number of subjects. In
this observational study of an adult asthma cohort in Korea
we found that the prevalence of AIA was 5.8%, based on
a questionnaire survey. AIA was associated with lower ageand a higher prevalence of rhinosinusitis and atopic
dermatitis. While no significant differences were seen in
lung function, asthma severity, medication use, and control
status, exacerbations were more common in the AIA
patients than in the ATA patients.
The prevalence of AIA of 5.8% in our study population
appears to be relatively low. Although there have been
a number of publications on AIA, controversy remains over
its prevalence, as this has been reported to range from 4%
to 44% according to the nationality of the subjects and the
evaluation method.14e19,27 Since the late 1990s, the re-
ported prevalence of AIA based on questionnaires
completed by randomly selected patients with asthma was
5.4% in Poland,16 8.8% in Finland,17 and 10e11% in
Australia.15 In Saudi Arabia,18 a review of medical records
Table 3 Severity classified by physicians and medication
status.
AIA
(n Z 68)
ATA
(n Z 1105)
P-value
Severity assessed
by the physicians
NS
Mild intermittent 4 (6.9) 55 (5.8)
Mild persistent 15 (25.9) 268 (28.4)
Moderate persistent 23 (39.7) 371 (39.3)
Severe persistent 16 (27.6) 249 (26.4)
Current use of
controllers
Use of three
or more controllers
22 (32.4) 263 (23.8) NS
Oral corticosteroid 6 (8.8) 55 (5.0) NS
Theophylline 9 (13.2) 81 (7.3) NS
Leukotriene modifier 18 (26.5) 256 (23.2) NS
Values are presented as numbers (%). AIA, aspirin-intolerant
asthma; ATA, aspirin-tolerant asthma; NS, not significant.
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asthma. Previous studies did not include any cohort of East
Asian asthmatics, and the Australian study, the last study
with a large number of subjects, was published almost
a decade ago. Thus, our figure of 5.8% could be of interest
as it is the most recently reported prevalence of AIA in
a large sample of East Asian asthmatic subjects. In our
study we used the questionnaire method to diagnose AIA,
and the prevalence was similar to that obtained in the
Polish study. The Australian and Polish studies gave
different results, even though they used similar methods,
and the Polish study also had a larger sample size (12,971
subjects).15e18 It has been suggested that differences in the
prevalence of AIA are caused by differences in study design
or surveyed population (general inhabitants vs. asth-
matics). In addition, the tools used for diagnosis and the
severity of asthma could make substantial contributions to
the variability in the measured prevalence of AIA.
There are some limitations associated with the use of
questionnaire methods for diagnosing AIA. In this study, as
in most others, AIA was diagnosed by a prior history ofTable 4 Healthcare utilization due to acute exacerbations, and
AIA (n Z 68)
Healthcare utilization ever 46 (67.6)
Healthcare utilization in the
previous 12 months
Any 21 (30.9)
Unscheduled OPD visit 8 (11.8)
ER visit 11 (16.2)
Asthma related hospitalization 6 (8.8)
ACT total score, mean  SD 20.8  3.3
Continuous values are presented as mean  SD, and categorical varia
tolerant asthma; ACT, Asthma Control Test (total score 25) Multivaria
test, presence of allergic rhinitis, and smoking status.intolerance for ‘aspirin or NSAIDs (cold medicine)’, based
entirely on the subjects’ memory. For that reason, some
provoking drugs might have been forgotten or misclassified.
In addition, we added the word ‘cold medicine’ for expla-
nation, because most over-the-counter cold medicines have
NSAIDs as their effective ingredient. Therefore, the possi-
bility cannot be denied that some patients experienced
asthma-like adverse reactions to other drugs than aspirin or
NSAIDs. Moreover, the basic problem with questionnaire
studies is the absence of any gold standard for diagnosis of
the disease of interest. Although a definitive diagnosis of
AIA can only be established using oral or inhalation chal-
lenge tests with increasing doses of aspirin, these are time-
consuming procedures and may cause serious complica-
tions. Accordingly, it would have been very difficult to
assess all participants using provocation tests in the present
cohort study. Chang et al.28 recently reported that a history
of aspirin hypersensitivity was the most reliable clinical
parameter for forecasting the outcome of the positive
aspirin challenge test, with an overall accuracy of 88.2%.
Nevertheless, due to the low sensitivity of aspirin hyper-
sensitivity for diagnosing AIA, the prevalence of AIA would
be higher if it was determined by an aspirin provocation
test rather than by using patient history.19
The TENOR study, which involved patients from the USA
and addressed severe or difficult-to-treat asthma, reported
a high prevalence of AIA (14%).14 Because patients with AIA
usually have a severe and prolonged clinical course, the
higher prevalence of AIA in patients with severe or difficult-
to-treat asthma compared with patients with mild-to-
moderate asthma is understandable. In this regard, the
differences in asthma severity and medication status
between the two groups were substantial in the TENOR
study. However, in the present study the prevalence of AIA
in the patients with moderate-to-severe asthma was 6.2%
(data not shown). Hence, it may not be the severity of the
subjects’ asthma, but differences between the assessed
populations, that are responsible for the variation in the
reported prevalence of AIA.
With regard to the relationship between the presence of
atopy and AIA, our data showed that AIA was associated
with atopic dermatitis and rhinosinusitis. Although uncer-
tainty remains, some previous studies have reported that
patients with AIA exhibit more clinical and immunologicallevel of asthma control.
ATA (n Z 1105) P-value OR (95% CI)
392 (35.5) <0.001 3.12 (1.85e5.56)
183 (16.6) 0.007 2.14 (1.23e3.75)
71 (6.4) 0.052 2.23 (1.00e4.98)
83 (7.5) 0.029 2.19 (1.08e4.42)
75 (6.8) 0.887 1.07 (0.44e2.60)
21.6  3.2 0.350 e
bles as numbers (%). AIA, aspirin-intolerant asthma; ATA, aspirin-
te regression analysis adjusted for age, gender, BMI, positive skin
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caria, positive skin tests, and high levels of total IgE and
eosinophilia in peripheral blood than those with
ATA.12,29e31 The incidence of rhinitis is strikingly high in
patients with AIA; previous surveys showed that approxi-
mately 80% of them had rhinitis.12,14 These findings are in
accord with those of the present study. However, there is
also a clinical study claiming the opposite effect.32
In the present survey, we found no significant differ-
ences in lung function and asthma severity between the
two groups. A very limited number of workers have
compared lung function in patients with AIA and those with
ATA. Chang et al. noted lower FEV1 in patients with AERD.
28
However, after logistic regression, this difference was not
significant. By contrast, the TENOR study demonstrated
that AIA was associated with decreased lung function and
increased asthma severity in patients with severe or
difficult-to-treat asthma. We enrolled patients with mild-
to-moderate as well as severe asthma, and this might be
the reason that we observed a lower prevalence of AIA and
no difference between asthma severity and lung function
between the two groups. However, although pulmonary
function data were not presented, the Australian15 and
Saudi Arabian18 patients with AIA suffered from more
severe asthma than those with ATA. In both of the previous
studies that enrolled patients suffering from asthma of all
levels of severity, the differences in asthma severity
between the two groups were significant. However, those
studies also reported a higher prevalence of AIA than we
found. In fact, it is possible that the underdiagnosis of AIA
among asthmatics in the present study was due to a low
sensitivity of the questionnaire for diagnosing AIA, and this
may also have contributed to the absence of significant
differences in lung function and asthma severity according
to presence of aspirin sensitivity.
It is notable that there was no significant difference in
gender bias between the two groups. A number of previous
studies reported a preponderance of women among those
with AIA.12,14,18,33,34 In contrast, an American study found
no difference according to gender.11 It has also been re-
ported that females tend to have higher rates of severe
asthma.34,35 The studies reporting these results also iden-
tified other characteristics that differed from the findings
of the present study, including a higher prevalence of AIA
among asthmatics and more severe asthma in patients with
AIA.14,15,18 Taken together, these observations suggest that
the differences in gender seen in the previous studies could
be due to the characteristics of the subjects with severe
asthma that were enrolled.
Interestingly, despite the absence of differences in lung
function and severity of asthma between the two groups in
the present study, a difference with respect to acute
exacerbation of asthma was observed according to clinical
criteria. Thus the patients with AIA visited the ER almost
twice as often as did those with ATA, as also seen in the
studies conducted in Australia and the USA.14,15 However,
the Australian study found increased asthma severity in the
patients with AIA, and the USA study reported not only
increased asthma severity but also decreased lung function
in those patients. Similarly, a study conducted in Japan
showed that patients who suffered multiple exacerbations
of asthma per year were much more likely to have NSAIDhypersensitivity and decreased lung function than those
who had one or less exacerbations in the previous year.36
Furthermore, the European Network For Understanding
Mechanisms Of Severe Asthma (ENFUMOSA) study,34 a cross-
sectional observational study comparing patients with
severe asthma and those with mild-to-moderate asthma,
and the Severe Asthma Research Program (SARP),37
a multicenter asthma research group funded by the
National Heart, Lung, and Blood Institute, both demon-
strated that aspirin sensitivity was more common in
subjects with severe asthma.
The definition of asthma control has two components:
current clinical asthma control and future risk.38,39 Clinical
parameters including symptoms, the degree to which
asthma impairs the patient’s usual activities, and lung
function are major indicators of the level of current clinical
asthma control.5 The future risk of exacerbation or disease
progression is also reflected in asthma control. In that
sense, this study reveals that aspirin hypersensitivity may
be a risk factor for acute exacerbation of asthma inde-
pendent of current clinical asthma control. Consistent with
this finding, in a comparison between a near-fatal asthma
group and a control asthma group based on a questionnaire
survey, AIA was strongly associated with near-fatal asthma,
whereas asthma severity did not differ significantly in the
two groups.27
In conclusion, in this first report of AIA in a large cohort
of Asian asthmatics, we found that the current prevalence
of AIA based on a questionnaire was 5.8% in Korea. Patients
with AIA were younger and had a higher prevalence of
rhinosinusitis and atopic dermatitis than those with ATA.
Multivariate analysis, adjusting for potential demographic
and clinical confounders, revealed no differences in lung
function and asthma severity between the two groups, but
AIA was associated with more frequent exacerbations.
These findings suggest that AIA is a distinct phenotype of
asthma, associated with a high likelihood of acute
exacerbations.
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